| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
2,3-Dehydrokievitone exhibits strong cytotoxic activity and induces apoptosis efficiently in cancer cells. It targets cancer cells and may induce apoptosis through mitochondrial or death receptor pathways. Its mechanism may involve disruption of cell cycle progression or induction of oxidative stress.
|
|---|---|
| ln Vitro |
In vitro, 2,3-Dehydrokievitone exhibits strong cytotoxic activity and induces apoptosis efficiently in cancer cells. It is a natural isoflavone with potential anticancer properties. Detailed in vitro data including IC50 values are limited.
|
| ln Vivo |
In vivo studies for 2,3-Dehydrokievitone are limited. Its strong cytotoxic activity suggests potential for cancer therapy. Animal studies are needed to confirm its in vivo efficacy and safety.
|
| Enzyme Assay |
Cell-free assays for 2,3-Dehydrokievitone: cytotoxic activity is assessed using cell-free systems such as enzyme inhibition assays (e.g., topoisomerase inhibition). Apoptosis induction is evaluated by measuring caspase activity in cell-free systems. Antioxidant activity is measured using DPPH and ABTS assays.
|
| Cell Assay |
Cellular assays for 2,3-Dehydrokievitone: cancer cell lines are cultured and treated with 2,3-Dehydrokievitone at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT assay. Apoptosis is assessed by Annexin V/PI staining, caspase activity, and PARP cleavage by Western blot. Cell cycle analysis is performed by propidium iodide staining.
|
| Animal Protocol |
In vivo animal studies for 2,3-Dehydrokievitone: xenograft mouse models of cancer would be used. Mice are implanted with cancer cells and treated with 2,3-Dehydrokievitone orally or intraperitoneally at doses of 10-50 mg/kg. Tumor growth, apoptosis markers, and toxicity are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,3-Dehydrokievitone: as a small isoflavone (molecular weight 354.36), it may have moderate oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. Tissue distribution and elimination pathways require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicity of 2,3-Dehydrokievitone: comprehensive toxicity data are limited. As a natural isoflavone, it is generally considered safe at moderate doses. However, high doses may have cytotoxic effects. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
2',4',5,7-Tetrahydroxy-8-isopentenyl isoflavone is a member of the isoflavone family. It has been reported that 2,3-dehydrovinyl isoflavone is found in common bean, yellow lupin, and other organisms with relevant data.
2,3-Dehydrokievitone is a research compound with potential applications in cancer research. It is available as a reference standard for pharmacological studies. Its mechanism involves cytotoxic activity and apoptosis induction. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C20H18O6
|
|---|---|
| Molecular Weight |
354.35
|
| Exact Mass |
354.11
|
| CAS # |
74161-25-4
|
| PubChem CID |
5746354
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
633.0±55.0 °C at 760 mmHg
|
| Flash Point |
229.8±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.690
|
| LogP |
5.08
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCc1c(cc(c2c1occ(c2=O)c3ccc(cc3O)O)O)O)C
|
| InChi Key |
RWDSADRZXTYPMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18O6/c1-10(2)3-5-13-16(23)8-17(24)18-19(25)14(9-26-20(13)18)12-6-4-11(21)7-15(12)22/h3-4,6-9,21-24H,5H2,1-2H3
|
| Chemical Name |
3-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8221 mL | 14.1103 mL | 28.2207 mL | |
| 5 mM | 0.5644 mL | 2.8221 mL | 5.6441 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
